Voy­ager bags a 'trans­for­ma­tion­al' $1.8B gene ther­a­py pact with Neu­ro­crine

Neu­ro­crine has bel­lied up to the deal ta­ble, snag­ging com­mer­cial rights to 4 gene ther­a­py de­vel­op­ment pro­grams at Voy­ager Ther­a­peu­tics — in­clud­ing their lead mid-stage treat­ment for Parkin­son-s dis­ease — for $165 mil­lion in cash split be­tween an up­front pay­ment and a $50 mil­lion eq­ui­ty stake, plus an­oth­er $1.5 bil­lion in mile­stone mon­ey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER